I. Lorimer

发表

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

L. Seymour, W. Miller, G. Batist, 2003, Clinical Cancer Research.

PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1

John Woulfe, Amin Kassam, A. Kassam, 2013, Oncotarget.

Predictive Biomarkers and Personalized Medicine PIK 3 CA , BRAF , andPTENStatus andBene fi t fromCetuximab in the Treatment of Advanced Colorectal Cancer — Results from NCIC CTG / AGITG CO . 17

P. Gibbs, N. Pavlakis, D. Tu, 2014 .

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

P. Gibbs, N. Pavlakis, D. Tu, 2013, Clinical Cancer Research.

Coordination of glioblastoma cell motility by PKCι

D. Gray, D. Parolin, I. Lorimer, 2010, Molecular Cancer.

Rescue and propagation of fully retargeted oncolytic measles viruses

C. James, S. Russell, K. Peng, 2005, Nature Biotechnology.

Interaction of Hsp90 with the Nascent Form of the Mutant Epidermal Growth Factor Receptor EGFRvIII*

J. Kelly, A. Klimowicz, D. Parolin, 2003, The Journal of Biological Chemistry.

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status

T. Zhao, I. Lorimer, J. Dimitroulakos, 2008, Journal of Neuro-Oncology.

Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor

G. Goss, I. Lorimer, J. Dimitroulakos, 2005, Clinical Cancer Research.

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

L. Seymour, H. Hirte, W. Miller, 2005, Investigational New Drugs.

Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate Pathway

G. Goss, I. Lorimer, J. Dimitroulakos, 2006, Clinical Cancer Research.

Induction of Premature Senescence by Hsp90 Inhibition in Small Cell Lung Cancer

I. Lorimer, I. Restall, Ian J. Restall, 2010, PloS one.

Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe.

I. Lorimer, S. Lavictoire, S. J. Lavictoire, 2000, Journal of immunological methods.

Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.

R. McLendon, A. Friedman, I. Pastan, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.

I. Lorimer, 2009, Cell cycle.

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

L. Gunaratnam, D. Parolin, I. Lorimer, 2003, The Journal of biological chemistry.

Mutant epidermal growth factor receptors as targets for cancer therapy.

I. Lorimer, 2002, Current cancer drug targets.

Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

D. Hayes, G. Pond, J. Dancey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

D. Hayes, G. Pond, J. Dancey, 2007 .

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2005, The New England journal of medicine.

Activation of p38MAPK Contributes to Expanded Polyglutamine-Induced Cytotoxicity

Douglas A. Gray, Matthew Y. Tang, Maria Tsirigotis, 2008, PloS one.

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

I. Pastan, M. Zalutsky, C. Foulon, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

125 I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts 1

I. Pastan, D. Bigner, M. Zalutsky, 1999 .

Repression of cancer cell senescence by PKCι

M. Daneshmand, D. Parolin, I. Lorimer, 2012, Oncogene.

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases

M. Clemons, M. Daneshmand, S. Dent, 2012, ISRN oncology.

BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.

M. Daneshmand, S. Verma, J. Weberpals, 2012, Oncology letters.

Induction of senescence in primary glioblastoma cells by serum and TGFβ

T. Perkins, I. Lorimer, Alexander Gont, 2017, Scientific Reports.

Inhibition of glioblastoma malignancy by Lgl1

A. Kassam, G. Nicholas, J. Woulfe, 2014, Oncotarget.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling

M. Rudnicki, T. Perkins, S. Weiss, 2016, Nature Neuroscience.

Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma Multiforme through de-repression of Bcl-xL translation

M. Holcik, F. Roncaroli, I. Lorimer, 2013, Oncotarget.

Regulation of glioblastoma cell invasion by PKCι and RhoB

D. Parolin, I. Lorimer, R. Baldwin, 2008, Oncogene.

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma

M. Daneshmand, D. Parolin, I. Lorimer, 2015, Cell cycle.

Aberrant Rac pathway signalling in glioblastoma

I. Lorimer, 2019, Small GTPases.

Avelumab in newly diagnosed glioblastoma

G. Nicholas, B. Nelson, J. Woulfe, 2021, Neuro-oncology advances.

Regulation of p27Kip1 by miRNA 221/222 in Glioblastoma

I. Lorimer, Jana K Gillies, Ian A J Lorimer, 2007, Cell cycle.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

J. Jett, F. Khuri, H. Choy, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cι-mediated attenuation of p38 MAP kinase signaling

P. Krzyzanowski, M. Andrade, D. Parolin, 2006, Oncogene.

Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells*

L. Gunaratnam, D. Parolin, I. Lorimer, 2003, Journal of Biological Chemistry.

Activation of extracellular-regulated kinases by normal and mutant EGF receptors.

I. Lorimer, S. Lavictoire, S. J. Lavictoire, 2001, Biochimica et biophysica acta.

PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion

J. Woulfe, M. Daneshmand, I. Lorimer, 2016, Oncotarget.

Engineered cells as glioblastoma therapeutics

I. Lorimer, Aparna Ramanathan, 2021, Cancer Gene Therapy.

Engineering PTEN-L for Cell-Mediated Delivery

W. Stanford, D. Gray, C. Vlasschaert, 2017, Molecular therapy. Methods & clinical development.

Modelling the Role of the Hsp70/Hsp90 System in the Maintenance of Protein Homeostasis

Carole J. Proctor, C. Proctor, I. Lorimer, 2011, PloS one.

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells

G. Goss, I. Lorimer, J. Dimitroulakos, 2003, Journal of Cancer Research and Clinical Oncology.

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

C. Addison, D. Jonker, J. Bar, 2012, Clinical & Experimental Metastasis.

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

C. Addison, D. Jonker, J. Bar, 2011, Clinical & Experimental Metastasis.

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.

J. Jett, M. Tsao, K. Ding, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Rac guanine nucleotide exchange factors promoting Lgl1 phosphorylation in glioblastoma

I. Lorimer, Alexander Gont, S. Lavictoire, 2020, bioRxiv.

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

L. Seymour, G. Batist, L. Panasci, 2005, Investigational New Drugs.

Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21

L. Seymour, M. Tsao, A. Sakurada, 2005 .

Induction of apoptosis in glioblastoma cells by an atypical protein kinase C pseudosubstrate peptide.

D. Parolin, I. Lorimer, S. J. Lavictoire, 2002, Anticancer research.

BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, D. Tu, 2012 .